Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
第2相
完了
NCT03671330
| 対象疾患 | Breast Cancer |
|---|
| 相 | 第2相 |
|---|
| スポンサー | Novartis Pharmaceuticals |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 327 名 |
|---|
| 介入（薬剤） | Ribociclib Placebo, Ribociclib, NSAI: Letrozole or Anastrazole, Goserelin |
|---|
| 開始日 | 2018年8月29日 |
|---|
| 完了日 | 2022年4月25日 |
|---|
| 結果公開日 | 2026年7月8日 |
|---|
概要
This was a randomized, double-blind, placebo-controlled study conducted in Chinese women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer, plus an open-label, single-arm pharmacokinetic (PK) subset in postmenopausal Chinese women with HR+, HER2- advanced breast cancer.
Pre and Postmenopausal Cohorts: Progressive Free Survival (PFS) Based on Local Assessment by RECIST 1.1 Guideline
After approximately 100 progression-free survival (PFS) events had been observed in each cohort, using data collected up to the analysis cut-off date of 25-Apr-2022, an average of 43 months. · Months
| Premenopausal Cohort - Ribociclib | 27.6 Months |
|---|
| Premenopausal Cohort - Placebo | 14.7 Months |
|---|
| Postmenopausal Cohort - Ribociclib | NA Months |
|---|
| Postmenopausal Cohort - Placebo | 18.5 Months |
|---|
| Hazard Ratio (HR) | 0.672 (95% CI 0.448–1.009) |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。